Stay updated on SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial

Sign up to get notified when there's something new on the SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The completed clinical trial record is displayed, with details on the semaglutide-versus-sitagliptin study, its design and outcomes, participating locations, results references, and study documents, replacing a 403 error screen.
    Difference
    100%
    Check dated 2026-11-07T12:40:09.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study details.
    Difference
    0.2%
    Check dated 2026-10-31T13:38:13.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    An NIH announcement banner was added about the transition from “artificial intelligence” to “Super Intelligence” terminology. The study record remains unavailable behind a 403 error.
    Difference
    1%
    Check dated 2026-10-24T13:04:18.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page remains a 403 Forbidden error screen, while its footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T13:18:15.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T14:03:42.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error instead of the previous study record content, indicating the page is blocked from access. The header/footer remain visible while the main content is replaced by an access-denied message.
    Difference
    22%
    Check dated 2026-09-19T18:07:44.000Z thumbnail image

Stay in the know with updates to SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SUSTAIN: Semaglutide vs Sitagliptin in Type 2 Diabetes Clinical Trial page.